GlassScriptPhysician profile
David M Anzai
NPI 1548323298
$4,121.94
in general payments reported to CMS, 2019-2025
20 companies · $716 in 2025
The $716 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $84.26 · 2021: $474 · 2022: $1,051 · 2023: $579 · 2024: $832 · 2025: $716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,069 · Gift: $58.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,068.55 |
| Gift | $58.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $730.07 | 2022-2025 | Xen Glaucoma Treatment System, Durysta |
| Bausch & Lomb Americas INC. | $655.99 | 2022-2025 | Xiidra, Miebo, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $375.22 | 2019-2021 | |
| Allergan, INC. | $257.66 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $237.46 | 2021-2025 | Cequa |
| Rxsight INC | $230.89 | 2024-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Glaukos Corporation | $198.67 | 2023-2025 | Idosetr, Istent Infinite |
| Alcon Vision LLC | $192.58 | 2022-2025 | Simbrinza, Rhopressa, Rocklatan |
| Aerie Pharmaceuticals, INC. | $188.15 | 2019-2021 | |
| Amgen INC. | $167.25 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $161.60 | 2022-2024 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $149.00 | 2023 | Tepezza |
| Topcon Healthcare, INC. | $111.38 | 2021 | |
| Kala Pharmaceuticals, INC. | $110.06 | 2021-2022 | |
| Sight Sciences, INC. | $98.93 | 2025 | Omni Surgical System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $88.50 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $76.87 | 2020-2023 | |
| Dompe US, INC. | $55.59 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $18.80 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $17.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Anzai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.